You are here

Exploring the Effects of Genomic Testing on Fear of Cancer Recurrence among Breast Cancer Survivors

Clicking RSVP will take you to a form. Please read the questions very carefully and select all - and only those - that apply.
Researcher
Maurade Gormley, MSN, Gail D’Eramo Melkus, EdD, ANP, FAAN, and Allison Vorderstrasse, APRN, DNSc, MSN, RN, New York University College of Nursing, New York, NY; Bradley E. Aouizerat, PhD, New York University College of Dentistry, New York, NY; Tish Knobf, PhD, RN, AOCN, FAAN, Yale University School of Nursing, New Haven, CT; and Marilyn Hammer, PhD, DC, RN, Mount Sinai Hospital Department of Nursing, New York, NY
Summary

The purpose of this research is to learn how the results of your Oncotype Dx® test results affect your health-related quality of life; your feelings of distress, anxiety, depression, and fear; and your perceived risk of recurrence. The researchers will use these findings to develop a personalized symptom management program to help improve the quality of life of breast cancer survivors.

What does participation involve?

A research team at New York University College of Nursing will use six short questionnaires to help them learn about your thoughts about and reactions to your Oncotype Dx® test results. If you are eligible for this study, you will first have a short phone call with the research team to review the consent form and provide verbal consent. You will then receive a link to the online questionnaires. The series of questionnaires will take about 15-30 minutes to complete. The series does not need to be completed in one sitting and you may skip questions. The researchers may also ask you to participate in a phone interview at a future date. The interview is voluntary and will take approximately 20-60 minutes.

Where?
Anywhere in the U.S.